| Wednesday, June 25, 2025 Abstract Session 44 – CRS – Biologics ROOM 9 (G6) | Level +1 09:10h – 10:25h ABSTRACTS |
| Chair: Luo Zhang |
| 3653 – Two-year data of tapered dupilumab shows high effectiveness in CRSwNP with NSAID-exacerbated respiratory disease |
| Elzinga Hester |
| 4313 – Anti-TSLP antibody induces rapid improvement in sinonasal symptoms following class-switching from other biologics |
| Ismael Heizo Nakano |
| 4524 – Access and reimbursement of biologics for chronic rhinosinusitis with nasal polyps: A survey of current practices |
| Abdool Wahed Amber |
| 3696 – Effects of Tezepelumab on eosinophilic chronic rhinosinusitis complicated by severe asthma |
| Wakasugi Ryo |
| 3782 – Superior Results with Mepolizumab and Sinus Surgery vs Mepolizumab Alone: 6-Month Randomised Trial |
| Homøe Anne-Sophie |
| 3791 – Stapokibart rapidly improves symptoms in patients with severe chronic rhinosinusitis with nasal polyps: a post-hoc analysis of the phase 3 CROWNS-2 trial |
| Zhou Yi |
| 3848 – Efficacy and safety of tezepelumab in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps: Results from the phase 3 WAYPOINT study |
| Hopkins Claire |
| 4105 – Sleep quality after biological treatment for chronic rhinosinusitis with nasal polyposis |
| Aldilaijan Khalid |
